19 patents
Utility
Extended Release Microparticles and Suspensions Thereof for Medical Therapy
23 Feb 23
An improved microparticle or lyophilized or otherwise reconstitutable microparticle composition thereof for medical therapy, including ocular therapy.
Ming Yang, Jeffrey L. Cleland, Yun Yu, Weiling Yu, Joshua Kays
Filed: 18 Nov 21
Utility
Extended Release Microparticles and Suspensions Thereof for Medical Therapy
23 Feb 23
An improved microparticle or lyophilized or otherwise reconstitutable microparticle composition thereof for medical therapy, including ocular therapy.
Ming Yang, Jeffrey L. Cleland, Yun Yu, Weiling Yu, Joshua Kays
Filed: 18 Nov 21
Utility
Aggregating microparticles for medical therapy
31 Jan 23
The present invention is a surface treated drug-loaded solid (e.g., non-porous) microparticle that aggregates in vivo to form a consolidated larger particle for medical therapy.
Yun Yu, Joshua Kays, Ming Yang, Jeffrey L. Cleland
Filed: 10 Sep 19
Utility
Drugs and compositions for the treatment of ocular disorders
10 Jan 23
The present invention provides new prodrugs of therapeutically active compounds, including oligomeric prodrugs, and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.
Ming Yang, John G. Bauman, Jeffrey L. Cleland, Nu Hoang, Emmett Cunningham
Filed: 20 Sep 19
Utility
New Equatorially Modified Polymer Linked Multimers of GUANSINE-3', 5'-CYCLIC Monophosphates
22 Dec 22
Embodiments of the invention are directed to new equatorially modified polymer linked multimers of guanosine-3′, 5′-cyclic monophosphate (cGMP) analogues that inhibit the cGMP-signaling system.
Hans-Gottfried Genieser, Frank SCHWEDE, Andreas RENTSCH, Per EKSTRÖM, Valeria MARIGO, Francois PAQUET-DURAND
Filed: 8 Aug 22
Utility
Equatorially modified polymer linked multimers of guanosine-3′, 5′-cyclic monophosphates
9 Aug 22
Embodiments of the invention are directed to new equatorially modified polymer linked multimers of guanosine-3′, 5′-cyclic monophosphate (cGMP) analogues that inhibit the cGMP-signaling system.
Hans-Gottfried Genieser, Frank Schwede, Andreas Rentsch, Per Ekström, Valeria Marigo, Francois Paquet-Durand
Filed: 29 Jun 17
Utility
Aggregating microparticles for medical therapy
17 May 22
The present invention is a surface treated drug-loaded solid (e.g., non-porous) microparticle that aggregates in vivo to form a consolidated larger particle for medical therapy.
Yun Yu, Joshua Kays, Ming Yang, Jeffrey L. Cleland
Filed: 10 Sep 19
Utility
Extended release microparticles and suspensions thereof for medical therapy
2 Nov 21
An improved microparticle or lyophilized or otherwise reconstitutable microparticle composition thereof for medical therapy, including ocular therapy.
Ming Yang, Jeffrey L. Cleland, Yun Yu, Weiling Yu, Joshua Kays
Filed: 10 May 18
Utility
Aggregated Microparticles
9 Sep 21
Compositions and methods are provided that include aggregating microparticles which include an active agent that exhibit an increased hardness and/or durability of the resulting aggregated microparticles in vivo, which can lead to more stable, long-term ocular therapy.
Ming Yang, Daniel Louis Salain, Charles Pauling Semba, Yun Yu, Weiling Yu, Joshua Kays, Jane Chisholm, Qingyun Lu, Jeffrey L. Cleland
Filed: 13 May 21
Utility
Compounds and Compositions for Ocular Delivery
15 Jul 21
The present invention provides new prodrugs of Sunitinib, Brinzolamide, and Dorzolamide and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.
John G. Bauman, Ming Yang, Nu Hoang, Emmett Cunningham, Jeffrey L. Cleland
Filed: 25 Mar 21
Utility
Continuous Microparticle Manufacture
25 Mar 21
The present invention is in the field of manufacturing drug-loaded microparticles, and specifically provides processes for producing approximately homogenously sized drug loaded microparticles with high drug loading and reproducible drug release profiles, and which may be provided in a significantly reduced time period.
Daniel Saragnese, Ming Yang, Yun Yu, Toni-Rose Guiriba, David McKenzie
Filed: 22 Oct 20
Utility
Drugs to Treat Ocular Disorders
11 Feb 21
The present invention provides new prodrugs of therapeutically active loop diuretics, including oligomeric prodrugs, and compositions to treat medical disorders, for example, ocular disorders such as glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.
Ming Yang, John G. Bauman, Jinzhong Zhang, Nu Hoang, Jeffrey L. Cleland
Filed: 22 Oct 20
Utility
Drugs and Compositions for Ocular Delivery
30 Sep 20
New prodrugs of therapeutically active compounds, including oligomeric prodrugs of ethacrynic acid, and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.
Jeffrey L. Cleland, Ming Yang, John G. Bauman, Nu Hoang, Jane Chisholm
Filed: 10 Jun 20
Utility
Extended Release Microparticles and Suspensions Thereof for Medical Therapy
22 Jul 20
An improved microparticle or lyophilized or otherwise reconstitutable microparticle composition thereof for medical therapy, including ocular therapy.
Ming Yang, Jeffrey L. Cleland, Yun Yu, Weiling Yu, Joshua Kays
Filed: 16 Mar 20
Utility
Drugs and Compositions for the Treatment of Ocular Disorders
29 Jan 20
The present invention provides new prodrugs of therapeutically active compounds, including oligomeric prodrugs, and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.
Ming Yang, John G. Bauman, Jeffrey L. Cleland
Filed: 19 Sep 19
Utility
Aggregating Microparticles for Medical Therapy
1 Jan 20
The present invention is a surface treated drug-loaded solid (e.g., non-porous) microparticle that aggregates in vivo to form a consolidated larger particle for medical therapy.
Yun Yu, Joshua Kays, Ming Yang, Jeffrey L. Cleland
Filed: 9 Sep 19
Utility
Aggregating Microparticles for Medical Therapy
1 Jan 20
The present invention is a surface treated drug-loaded solid (e.g., non-porous) microparticle that aggregates in vivo to form a consolidated larger particle for medical therapy.
Yun Yu, Joshua Kays, Ming Yang, Jeffrey L. Cleland
Filed: 9 Sep 19
Utility
Compounds and compositions for the treatment of ocular disorders
25 Nov 19
The disclosure describes prodrugs and derivatives of prostaglandins, carbonic anhydrase inhibitors, kinase inhibitors, beta-adrenergic receptor antagonists and other drugs, as well as controlled delivery formulations containing such prodrugs and derivatives, for the treatment of ocular disorders.
Jeffrey L. Cleland, Ming Yang, John G. Bauman, Nu Hoang, Emmett Cunningham
Filed: 15 Oct 18
Utility
Aggregating microparticles for medical therapy
14 Oct 19
The present invention is a surface treated drug-loaded solid (e.g., non-porous) microparticle that aggregates in vivo to form a consolidated larger particle for medical therapy.
Yun Yu, Joshua Kays, Ming Yang, Jeffrey L. Cleland
Filed: 10 Nov 16
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first